This National Cancer Policy Forum workshop will provide a venue for the cancer community to examine the impact of evolving trends in cancer incidence and care on the oncology careforce.
AACI Update | February 2019
Headlines
$30 Million Gift Will Transform University of Alabama Cancer Center
Join Us for the 2019 AACI/AACR Hill Day
AACI and the American Association for Cancer Research (AACR) will co-host the 2019 Hill Day in Washington, DC, on Tuesday, April 30. AACI is encouraging its U.S. members to send at least one representative to Washington to advocate on your center’s behalf—and this year, for the first time, AACI will offer scholarships to support the participation of patient advocates at Hill Day, giving them an opportunity to share their impactful stories with legislators.
CAR T Listserv Now Open to AACI Members
AACI has launched a CAR T listserv to allow for greater engagement among members who want to share best practices, challenges, and solutions related to CAR T-cell therapy implementation. The listserv was created as part of the larger CAR T Initiative, which aims to help guide AACI members in implementing CAR T-cell therapy programs at cancer centers across North America. The CAR T listserv is open only to AACI members.
AACI Welcomes ASTRO as New Sustaining Member
Call for Abstracts for the 11th Annual AACI CRI Meeting
The AACI Clinical Research Innovation (CRI) Steering Committee is currently soliciting abstracts for the 11th Annual AACI CRI Meeting that will be held July 9-11 in Chicago. This year’s meeting theme will focus on strategies to maximize innovation to advance cancer clinical research. The purpose of the abstracts is to inform meeting attendees about clinical trials office challenges and solutions implemented at AACI cancer centers.
AACI Changes, Member Benefits Featured in Report
2018 was a year of transitions for AACI—a new president and executive director, fresh initiatives, a redesigned website and newsletter, and an expanded staff to better serve AACI’s 98 cancer center members. These are just a few of the highlights covered in the 2018 AACI Report.
In 2019, AACI will continue to develop programming that supports the interests of its members and provide peer-to-peer networking opportunities for cancer center leadership.
In 2019, AACI will continue to develop programming that supports the interests of its members and provide peer-to-peer networking opportunities for cancer center leadership.
News from the Centers
Gerson Tapped for Biden Cancer Working Group
Case Comprehensive Cancer Center
AACI Immediate Past President Stanton L. Gerson, MD, director, Case Comprehensive Cancer Center, has been named to the Biden Cancer Initiative Data Sharing Working Group. The group's goal is to gather evidence to show that standardized collection of a new minimum set of cancer-specific data elements can inform better clinical decision making and alignment within the cancer community.
Weiner Named a National Academy of Inventors Fellow
Georgetown Lombardi Comprehensive Cancer Center
The National Academy of Inventors (NAI) has named Louis M. Weiner, MD, director of Georgetown Lombardi Comprehensive Cancer Center, to its 2018 class of fellows. An internationally recognized medical oncologist specializing in the treatment of gastrointestinal cancers, Dr. Weiner is also an accomplished immunotherapy researcher.Neurosurgeon-scientist Honored for Work in Lab, Clinic
UCLA Jonsson Comprehensive Cancer Center
Linda Liau, MD, PhD, MBA, has been awarded the Abhijit Guha Award for her pioneering work on treating brain tumors. Established in memory of the late Dr. Abhijit Guha, the award is jointly sponsored by the Society for Neuro-Oncology and the Joint Section on Tumors of the American Association of Neurological Surgeons and the Congress of Neurological Surgeons.Soper Inducted into AIMBE College of Fellows
The University of Kansas Cancer Center
Steven Soper, PhD, was elected to the American Institute for Medical and Biomedical Engineering (AIMBE) College of Fellows. The AIMBE College of Fellows represents the top 2 percent of the medical and biological engineering community. Dr. Soper is a leading researcher in the generation of novel biomedical devices, concentrating on in vitro cancer diagnostics based on lab-on-a-chip technologies.Puzanov Honored for Melanoma Research
Roswell Park Comprehensive Cancer Center
Igor Puzanov, MD, MSci, FACP, was honored for his “outstanding and lifelong contributions to melanoma research” during the just-concluded Melanoma and Immunotherapy Bridge research meeting in Naples, Italy. Dr. Puzanov, who is chief of melanoma and director of the Early Phase Clinical Trials Program at Roswell Park, received the award from Italy’s Fondazione Melanoma, or Melanoma Foundation.Khabele Elected as ASCI Member
The University of Kansas Cancer Center
Dineo Khabele, MD, director of The University of Kansas Cancer Center’s gynecologic oncology division, has been elected a new member to the American Society for Clinical Investigation (ASCI) for 2019. Dr. Khabele is one of five physician-scientists in the history of KU Medical Center to be elected to ASCI, and she is one of only three gynecologic oncologists to ever receive it.Ruckdeschel Named to Lung Roundtable
UMMC Cancer Center and Research Institute
John Ruckdeschel, MD, University of Mississippi Medical Center Cancer Institute director, has been named to the National Lung Cancer Roundtable. Established by the American Cancer Society in 2017, the roundtable gathers experts dedicated to reducing the incidence of and deaths from lung cancer through appropriate screening, treatment, and prevention services.Chen Honored with Chair in Oncology
Winship Cancer Institute of Emory University
Jing Chen, PhD, professor and director of the Division of Basic & Translational Science in the Department of Hematology and Medical Oncology in the Emory University School of Medicine, has been named the R. Randall Rollins Chair in Oncology.Osley Appointed to NCI Board for Basic Sciences
University of New Mexico Comprehensive Cancer Center
Mary Ann Osley, PhD, has been appointed to a four-year term on the NCI Board of Scientific Counselors for Basic Sciences, which advises on scientific program policy and the direction of basic science research programs. Dr. Osley leads the Cancer Genetics, Epigenetics and Genomics Research Group at the University of New Mexico Comprehensive Cancer Center.
Immunologist Named AAAS Fellow
O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham
John F. Kearney, PhD, has been named a fellow of the American Association for the Advancement of Science (AAAS). Dr. Kearney was elected in the Medical Sciences section of AAAS “for his distinguished contributions to immunology, particularly in understanding B cell development and the role of B cells in autoimmune diseases.”Waller Awarded Professorship
Winship Cancer Institute of Emory University
The inaugural Rein Saral, MD Professorship in Cancer Medicine was awarded to Edmund K. Waller, MD, PhD, a distinguished Winship Cancer Institute of Emory University investigator and physician. The professorship recognizes Dr. Waller's outstanding contributions and expertise in the area of hematological malignancies and bone marrow/stem cell transplantation.Lonial Honored with Gray Family Chair in Cancer
Winship Cancer Institute of Emory University
Sagar Lonial, MD, chief medical officer for Winship Cancer Institute of Emory University, was honored with the Anne and Bernard Gray Family Chair in Cancer. The endowment honors the life of Mrs. Gray's sister, Karen Ammons Howell, who died of breast cancer.
Slamon Awarded Prize for Pioneering Research
UCLA Jonsson Comprehensive Cancer Center
Dennis Slamon, MD, PhD, director of the Revlon/UCLA Women’s Cancer Research Program, has been named a co-winner of the 2019 Sjöberg Prize by the Royal Swedish Academy of Sciences and Sweden’s Sjöberg Foundation. Honored for his groundbreaking research in targeted cancer therapies, Dr. Slamon shares the award with Brian Druker, MD, of Oregon Health & Science University.Dhodapkar Awarded Inaugural Brock Chair
Winship Cancer Institute of Emory University
Madhav V. Dhodapkar, MBBS, director of Winship Cancer Institute's new Center for Cancer Immunology, has been honored as the inaugural holder of the Anise McDaniel Brock Chair. He was also named a Georgia Research Alliance Eminent Scholar in Cancer Innovation at a ceremony in February.Plimack Elected to Board of American Society of Clinical Oncology
Fox Chase Cancer Center, Temple Health
Elizabeth Plimack, MD, MS, professor and chief of the Division of Genitourinary Medical Oncology at Fox Chase Cancer Center, has been elected to the American Society of Clinical Oncology Board of Directors for a term of four years. She will begin her appointment in June 2020 and is eager to represent Fox Chase as she works to encourage collaboration and methods of sharing information in oncology.Pelotonia 2018 Generates More Than $27 Million for Cancer Research
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Pelotonia riders and volunteers raised a record-breaking $27.4 million through the 2018 event to benefit cancer research at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute. This brings the 10-year total to more than $184 million.$26 Million 'Grand Challenge' Project Will Probe Role of Inflammation in Cancer
UCSF Helen Diller Family Comprehensive Cancer Center
UC San Francisco Professor Thea Tlsty, PhD, is a winner of the “Grand Challenge” competition sponsored by Cancer Research UK, an ambitious funding initiative that aims to answer some of the biggest questions in cancer. Tlsty’s international team will receive $26 million to uncover how chronic inflammation drives some of the most aggressive forms of cancer.Grant to Support Study of E-Cigs, Oral Health
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Researchers at the OSUCCC - James, led by Purnima Kumar, DDS, PhD, have landed a five-year, $3.12 million grant from the National Institute of Dental and Craniofacial Research for the first comprehensive examination of biological responses to electronic nicotine delivery systems, or e-cigs.
NCI-Funded Study Aims to Enhance Glioblastoma Treatment
Cleveland Clinic Cancer Center
Jeongwu Lee, PhD, was awarded a five-year, $2.4 million grant from the National Cancer Institute, part of the National Institutes of Health, to study an FDA-approved drug to enhance treatment of glioblastoma, the most common and lethal form of brain cancer.Researchers Investigate Nanoimmunotherapies for Cancer
GW Cancer Center
A GW Cancer Center team has engineered a nanoimmunotherapy combining the advantages of nanotechnology and immunotherapy to treat cancer. The goal of this combination is to increase the potency of immune checkpoint inhibitors to a significantly larger proportion of patients. Rohan Fernandes, PhD, received more than $1.6 million from the National Institutes of Health for the study.
Grant Helps Unravel Role of Glucose, Fats in Bone Cancer
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
A $1.2 million Department of Defense grant has been awarded to Theresa Guise, MD, whose research explores a cascade of events that decreases quality of life and treatment responses for patients with metastatic bone cancer. Her work aims to understand the role of the tumor-bone microenvironment on glucose metabolism and the role of a high-fat diet in the process.Department of Defense Awards Nearly $1 Million to Study Prostate Cancer Drug Resistance
Case Comprehensive Cancer Center
As part of their Idea Award program, the Department of Defense has awarded Sanjay Gupta, PhD, MS, a total of $962,000 over three years to investigate drug resistance mechanisms in prostate cancer. The program aims to improve quality of life by decreasing the impact of cancer on active duty service members and their communities.$75 Million Gift to Establish Blood Cancer Center
Laura and Isaac Perlmutter Cancer Center at NYU Langone
An anonymous $75 million gift to NYU Langone Health and its Laura and Isaac Perlmutter Cancer Center will establish a Center for Blood Cancers housing a new, world-class program for multiple myeloma care and research. The new center will significantly expand the center’s capacity to study and treat blood cancers.Patient Feedback Improves Cancer Treatments
Cedars-Sinai Cancer
A major new study now underway aims to better incorporate patient feedback into clinical trials that help determine which new cancer treatments will be approved for use. The project, supported by a five-year, $3.4 million grant from the National Cancer Institute, involves statisticians, clinicians, and patient advocates. The team is analyzing data from previous and ongoing clinical trials to design new statistical measurement criteria for assessing how well trial participants tolerate experimental therapies.NCI Awards Lymphoma SPORE Grant
City of Hope Comprehensive Cancer Center
City of Hope has received its third lymphoma Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI), one of four current NCI-supported lymphoma SPORE grants. It covers a five-year period and totals $12.5 million. This interdisciplinary research is currently advanced in the Toni Stephenson Lymphoma Center, which is the foundation of City of Hope's Hematologic Malignancies and Stem Cell Transplantation Institute.Grant Advances Ovarian Cancer Early Detection Efforts
The University of Kansas Cancer Center
Researchers at The University of Kansas Cancer Center have received a three-year, $900,000 grant from the Ovarian Cancer Research Alliance to better understand why epithelial ovarian cancers take decades to develop as well as identify methods for early detection. Epithelial ovarian cancer accounts for about 90 percent of all ovarian cancer cases. Andrew Godwin, PhD, is principal investigator.Brawley to Direct Outreach, Disparities Research
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Otis W. Brawley, MD, former chief medical and scientific officer for the American Cancer Society, has been named a Bloomberg Distinguished Professor at Johns Hopkins University. He will lead interdisciplinary research on cancer health disparities and outreach programs as Sidney Kimmel Cancer Center’s associate director for community outreach and engagement.
Geneticist Joins UMMC Cancer Institute
UMMC Cancer Center and Research Institute
Yann Gibert, PhD, has joined the University of Mississippi Medical Center Cancer Institute as an associate professor in the CI Cancer Molecular Biology Program and as an associate professor in the UMMC Department of Cell and Molecular Biology.Patel to Lead Multidisciplinary Cutaneous Oncology Program
GW Cancer Center
The George Washington University (GW) Cancer Center has announced that Vishal A. Patel, MD, FAAD, FADMC, has joined the cancer center. He will serve as the director of the recently established Cutaneous Oncology Program. Dr. Patel most recently led the Division of Dermatologic Surgery and directed the High Risk Skin Cancer Clinic at Columbia University in New York City.
Artificial Intelligence Officer Hired
Moffitt Cancer Center
J. Ross Mitchell, PhD, has joined Moffitt Cancer Center as the artificial intelligence officer. The new role will lead the development of digital tools that utilize computer science to improve cancer care. A senior member of Moffitt's Department of Biostatistics and Bioinformatics, Mitchell will collaborate with fellow research faculty to optimize projects with artificial intelligence (AI) applications.
Hazlehurst Named Associate Director
WVU Cancer Institute
Lori Hazlehurst, PhD, has been named as the associate director for basic research at the WVU Cancer Institute. In this role, she will work closely with the leadership team of the institute to implement strategic goals to increase the impact of basic and translational cancer research at WVU. The primary strategy is to increase the number of NIH-funded investigators focused on cancer research at WVU.Medical Director Named for Center for Brain and Spine Metastasis
Duke Cancer Institute, Duke University Medical Center
Medical oncologist Carey Anders, MD, has been appointed medical director for the DCI Center for Brain and Spine Metastasis and has joined the Breast Medical Oncology group. Previously, Dr. Anders was leader of the University of North Carolina at Chapel Hill Breast Section.Meyerson Named Chief of Thoracic Surgery
UK Markey Cancer Center
Thoracic surgeon and educator Shari Meyerson, MD, MEd, has joined UK HealthCare as the new chief of thoracic surgery. Meyerson will direct the section of thoracic surgery as well as provide surgical leadership to the thoracic oncology team at the UK Markey Cancer Center. She comes to UK after nearly a decade at Northwestern University.New Vice Chair of Genitourinary Oncology Announced
Moffitt Cancer Center
Manish Kohli, MD, has joined Moffitt Cancer Center as the vice chair of the Department of Genitourinary Oncology. He has an extensive research background, focusing on bringing individualized care to patients. Dr. Kohli joins Moffitt from the Mayo Clinic, Rochester, where he conducted clinical trials in advanced stages of prostate, kidney, bladder, and testicular cancers.
Director Steps Down, Interim Leader Appointed
Hollings Cancer Center, Medical University of South Carolina
Gustavo Leone, PhD, director of the MUSC Hollings Cancer Center, has announced that he has accepted a position as director of the Medical College of Wisconsin Cancer Center. He will work with the interim director, Denis C. Guttridge, PhD, to ensure a smooth transition. Dr. Leone plans to leave the university on April 15.Eckert Named Deputy Director
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Richard L. Eckert, PhD, has been named deputy director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC). Dr. Eckert, a preeminent scientist and investigator with continuous funding from the National Institutes of Health, has served as the UMGCCC associate director for basic sciences since 2013.Milligan Named HCI Cancer Hospital Executive Director
Huntsman Cancer Institute at the University of Utah
Huntsman Cancer Institute (HCI) and University of Utah (U of U) Health Hospitals and Clinics have announced that Don Milligan, MBA, will serve as the new executive director of the HCI Cancer Hospital. Milligan has more than 25 years of management experience in health care, 22 of which have been in leadership roles at U of U Health and HCI.
MSK Appoints Chief Marketing and Communications Officer
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSK) has appointed Roxanne Taylor as chief marketing and communications officer, effective February 3. Taylor will be responsible for shaping and enhancing the MSK brand and will be accountable for building the long-term equity of the brand with all stakeholders.Khabele Named Head of Obstetrics and Gynecology
Siteman Cancer Center
Gynecologic oncologist Dineo Khabele, MD, noted for her expertise in ovarian cancer research and treatment, has been named head of the Department of Obstetrics & Gynecology at Washington University School of Medicine and Siteman Cancer Center. Dr. Khabele, whose appointment becomes effective June 1, also will be installed as the Mitchell and Elaine Yanow Professor of Obstetrics & Gynecology.New Associate Director of Community Outreach and Engagement Announced
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center announces the appointment of Cheryl L. Knott, PhD, as associate director of community outreach and engagement. Dr. Knott has more than 20 years of experience in community-based cancer control research, with a strong focus on eliminating cancer disparities.
New Associate Directors Tapped for Data, Population Sciences
University of Michigan Rogel Cancer Center
The University of Michigan Rogel Cancer Center has named two new associate directors. Bhramar Mukherjee, PhD, will be the associate director for quantitative data sciences, and Christopher Friese, PhD, RN, was named associate director for cancer control and population sciences.Director of Finance Named
Duke Cancer Institute, Duke University Medical Center
Steven Bender, MBA, FHFMA, formerly senior director of finance for Florida Atlantic University College of Medicine in Boca Raton, has been named director of finance of Duke Cancer Institute (DCI). Bender assumed his new role January 6. He serves as the architect of financial reports and models, which support DCI as a blended school of medicine and health system operation.Improved Understanding of Renal Cell Cancer Mutations, Identification of Biomarkers May Inform Future Treatment
Fox Chase Cancer Center, Temple Health
While renal cell cancer treatments have improved as researchers gained a deeper understanding of the disease’s genetics and genomics, there is an opportunity to make a greater difference by identifying biomarkers and mutations that will help oncologists select the most effective treatments for individual patients, according to a recent paper by Daniel M. Geynisman, MD.Advanced Drug Delivery System with Highest Tumor-Targeting Ability Developed
VCU Massey Comprehensive Cancer Center
In pre-clinical studies, VCU Massey Cancer Center scientists, led by Hu Yang, PhD, have developed a novel drug delivery system using nanoparticles that significantly outperformed the tumor-targeting abilities of its predecessors. The researchers are hopeful their findings could lead to improved outcomes and reduced side effects for cancer patients undergoing chemotherapy.Researchers Aim to Develop Radiation Therapy with Short Exposure Times
Stanford Cancer Institute
New accelerator-based technology being developed by the Department of Energy’s SLAC National Accelerator Laboratory and Stanford University aims to reduce the side effects of cancer radiation therapy by shrinking its duration from minutes to under a second. Researchers at SLAC and Stanford received funding to develop two possible treatments for tumors — one using X-rays, the other using protons.HPV Discovery Raises Hope for New Cervical Cancer Treatments
University of Virginia Cancer Center
Researchers at the University of Virginia School of Medicine have made a discovery about human papillomavirus (HPV) that could lead to new treatments for cervical cancer and other cancers caused by the virus. Anindya Dutta, PhD, and his colleagues have determined that an enzyme called USP46 is essential for HPV-induced tumor formation and growth. The enzyme promises to be very susceptible to drugs.Improved Survival Shown in Pediatric Hodgkin Lymphoma Patients When Receiving Combined Modality Treatment
Rutgers Cancer Institute of New Jersey
Research from Rutgers Cancer Institute of New Jersey shows improved overall survival at five years for pediatric patients with early-stage Hodgkin lymphoma when treated with chemotherapy followed by radiotherapy versus chemotherapy alone. The work is believed to be the largest retrospective study to date involving this population.Personalized Medicine Tool Developed for Inherited Colorectal Cancer Syndrome Risk
Huntsman Cancer Institute at the University of Utah
An international team of researchers led by Huntsman Cancer Institute at the University of Utah has developed, calibrated, and validated a novel tool for identifying the genetic changes in Lynch syndrome genes that are likely to be responsible for causing symptoms of the disease.Tumor Microenvironment Targeted to Shut Down Liver Cancer
VCU Massey Comprehensive Cancer Center
For nearly a decade, VCU Massey Cancer Center researcher Devanand Sarkar, PhD, has uncovered new insights into the development and progression of liver cancer, identifying key genetic drivers and shedding light on unknown associations with obesity and inflammation. He and his colleagues have set their sights on immune cells found in the liver called macrophages, and their findings could lead to novel treatment approaches.
Engineered Immune Cells Target Pediatric Solid Tumors in Mice
Stanford Cancer Institute
Immune cells engineered to attack childhood cancers were able to eradicate different types of pediatric tumors in mice, according to a new study from the Stanford University School of Medicine. The study provides evidence that these engineered cells can target many types of pediatric solid tumors, including brain tumors. Robbie Majzner, MD, is lead author of the study.Cancer Drugs Speed Repair in Lungs Damaged by Bacterial Infections
Duke Cancer Institute, Duke University Medical Center
Cancer drugs are able to halt life-threatening bacterial lung infections in mouse models by promoting lung repair, researchers at Duke Health have found. If the findings are confirmed in human studies, the drugs could point to a new weapon against bacterial pneumonia, which afflicts 50,000 people in the U.S. each year. Ann Marie Pendergast, PhD, is the study's senior author.Exciting Early Results in Trial of Immunotherapy for Myeloma
Fred Hutchinson Cancer Center
Eleven patients had already received numerous treatments for their cancers, some as many as 20 different courses of therapy. Yet their myelomas, almost all classified as “high risk,” kept coming back. These patients were part of a clinical trial led by Damian Green, MD, for a new experimental, immune-harnessing therapy, whose design includes features based on research at Fred Hutchinson Cancer Research Center.Christmas Berry Plant Could Fight Uveal Melanoma
Sidney Kimmel Cancer Center at Jefferson Health
Researchers at the Sidney Kimmel Cancer Center at Jefferson Health and the Icahn School of Medicine at Mt. Sinai have found that a compound extracted from the Christmas berry primrose plant stops the growth of uveal melanoma—a cancer of the eye—in preliminary tests. With further testing, the discovery could lead to new therapeutic options for patients with the cancer.
Complication Rates, Costs of Invasive Lung Cancer Diagnostic Tests May Be Higher Than Expected
The University of Texas MD Anderson Cancer Center
Complication rates following invasive diagnostic procedures for lung abnormalities were twice as high in the community setting compared to those reported in lung cancer screening trials, and associated downstream costs ranged from $6,320 to $56,845 on average, according to a new study from The University of Texas MD Anderson Cancer Center.Sprayable Gel Could Help Body Combat Cancer After Surgery
UCLA Jonsson Comprehensive Cancer Center
Many people who are diagnosed with cancer will undergo some type of surgery to treat their disease. But despite improvements in surgical techniques over the past decade, the cancer often comes back after the procedure. Now, a UCLA-led research team has developed a spray gel embedded with immune-boosting drugs that could help. In a peer-reviewed study, the substance was successful half of the time in awakening lab animals’ immune systems to stop the cancer from recurring and inhibit it from spreading to other parts of the body.New Algorithm Improves Online Survey Data Reliability
Fox Chase Cancer Center, Temple Health
Elizabeth Handorf, PhD, has developed a new method that makes analysis of data collected online more reliable by eliminating repeat responders. Her method identifies clusters of non-independent enrollments that administrators of a study could not otherwise detect. When these low quality participants are omitted from a study, its efficacy can be measured with greater accuracy.Study Unveils 40 New Mutations Linked to Colorectal Cancer
Fred Hutchinson Cancer Center
A group of colorectal cancer researchers are using the word “milestone” to describe their new genomic research. The product of more than five years’ work by scientists at 130 institutions, the paper presents results from the most comprehensive genome-wide association study (GWAS) of colorectal cancer risk done to date. Among their findings: 40 new inherited mutations that put people at risk for colorectal cancer, or CRC, the second-deadliest cancer in the world.Opioid Prescriptions Can Be Drastically Reduced After Surgery with No Increase in Pain
Roswell Park Comprehensive Cancer Center
A two-year study by a multidisciplinary team of surgeons and other cancer specialists found that the amount of opioid medications prescribed after surgery can be drastically reduced without negatively affecting pain scores, postoperative complications, or patient requests for additional opioids. Emese Zsiros, MD, PhD, FACOG, is senior author of the study.New Insights Regarding Genetic Contribution to Inherited Prostate Cancer
Sidney Kimmel Cancer Center at Jefferson Health
Newly published research from Sidney Kimmel Cancer Center at Jefferson Health investigators provides a snapshot of the spectrum of genetic changes that are responsible for inherited prostate cancer, supporting current guidelines for genetic testing of patients with prostate cancer, as well as suggesting expanded testing to encompass additional patients.Targeting an 'Energy Crisis' in the Treatment of Non-Small Cell Lung Cancer
Rutgers Cancer Institute of New Jersey
When it comes to stopping a common form of lung cancer, an energy crisis is a good thing. Research from investigators at Rutgers Cancer Institute of New Jersey examined a potential approach to cancer therapy that disrupts a cancer cell’s "fuel supply" by targeting a cellular survival mechanism known as autophagy. "Jessie" Yanxiang Guo, PhD, is the senior author of the work.Team Finds Promise in Precision Medicine Approach to Osteosarcoma
UCSF Helen Diller Family Comprehensive Cancer Center
Using a divide and conquer strategy, researchers from the University of California San Francisco have provided a roadmap for the development of a precision medicine approach to osteosarcoma, the most common bone cancer in children and young adults, for which treatment has remained unchanged for more than 30 years. E. Alejandro Sweet-Cordero, MD, is lead author of the study.Study Shows Progress Toward Melanoma Prevention
UK Markey Cancer Center
A team of University of Kentucky researchers led by Stuart Jarrett, PhD, and John D’Orazio, MD, PhD, have discovered specific protein interactions that may help cells resist ultraviolet damage and carcinogenesis. The study focused on the role of a cell receptor found in melanocytes known as the melanocortin 1 receptor.Expanded Cord Blood Promising for Use in Adult Bone Marrow Transplants
Duke Cancer Institute, Duke University Medical Center
Umbilical cord blood stem cells that are cultured and expanded outside the body before being used for bone marrow transplant in adult blood cancer patients appear safe and restore blood count recovery faster than standard cord blood. The findings, led by Mitchell Horwitz, MD, are from a Phase I/II study of the biologic treatment, NiCord, at 11 clinical trial sites.Drug Target Identified for Chemotherapy-Resistant Ovarian, Breast Cancer
Siteman Cancer Center
Washington University researchers at Siteman Cancer Center may have found a path toward improving the effectiveness of chemotherapy in people with breast or ovarian cancer that is caused by BRCA defects. They have identified a pair of genes that operate in parallel to BRCA. Knocking down the genes increases tumor cells’ susceptibility to a toxic chemical – and potentially to chemotherapy drugs as well.Genetic, Metabolic Differences May Explain Diet, Cancer Study Variations
Roswell Park Comprehensive Cancer Center
A new study led by Susan McCann, PhD, RD, examines how women of different backgrounds metabolize lignans. What scientists learned may help explain why associations between diet and breast cancer risk have been difficult to demonstrate consistently.Risk-Adapted Approach to Assessing Kidney Tumor Complexity Recommended
Fox Chase Cancer Center, Temple Health
By diving deep into data about more than 1,300 past kidney cancer cases, Fox Chase Cancer Center researchers, led by Robert G. Uzzo, MD, FACS, concluded that there is no compelling cancer-related reason to remove an entire kidney solely based on a tumor’s location in the hilum. Instead, other factors should provide more weight in risk-adapted decisions about whether to do a partial or a radical nephrectomy.How to Boost Cancer Clinical Trial Participation
Fred Hutchinson Cancer Center
How do you make cancer clinical trials available to more patients? A new study led by Joseph Unger, PhD, MS, at Fred Hutchinson Cancer Research Center offers a tantalizing solution: loosen up the strict eligibility criteria. In a nutshell, the research found that physicians often don’t even discuss potential trial participation with patients who are ineligible due to having another disease.Lymph Nodes May Help Determine Course of Pleural Mesothelioma
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
University of Maryland School of Medicine surgeons have identified a group of lymph nodes in the chest that appear highly significant in predicting the prognosis for patients with malignant pleural mesothelioma. The researchers found that presence of cancer in these lymph nodes increased the risk of recurrence or death more than two-fold in patients undergoing mesothelioma surgery.Novel Strategy for Therapy-Resistant Melanoma with Mutations in the BRAF Gene
Ellen and Ronald Caplan Cancer Center of The Wistar Institute
Collaborative research by The Wistar Institute and Moffitt Cancer Center has demonstrated that BRAF-targeted therapies render resistant melanoma more sensitive to the attack of killer T cells. This result suggests that adoptive T cell therapy may benefit patients that have become resistant to BRAF inhibitors.Researchers Develop Urine Test for Bladder Cancer
Stanford Cancer Institute
Researchers at the Stanford University School of Medicine have developed a highly sensitive urine test for diagnosing and monitoring bladder cancer. The test involves looking for fragments of cancer DNA in urine samples.Study: Survival Benefit for Black Men on New Prostate Cancer Drugs
Duke Cancer Institute, Duke University Medical Center
Recent research led by scientists at the Duke Cancer Institute shows better overall survival rates among black men with metastatic disease who are treated with abiraterone acetate or enzalutamide. Megan Ann McNamara, MD, presented the research at a meeting of the American Society of Clinical Oncology in February.A Long Shot Could Bear Fruit
University of New Mexico Comprehensive Cancer Center
UNM Comprehensive Cancer Center's Jeffrey Arterburn, PhD, a medicinal chemist, and Eric Prossnitz, PhD, a molecular biologist, screened thousands of compounds to find two that interact with a receptor called GPER. A startup company, Linnaeus, has licensed one of those compounds to use in combination with an immunotherapy agent and will begin clinical trials in melanoma.Bioluminescent Deep-Sea Creatures Illuminate Effectiveness of New Cancer Therapies
USC Norris Comprehensive Cancer Center
Researchers at the Keck School of Medicine of USC have developed a new laboratory tool, which is poised to improve the development and effectiveness of a burgeoning group of therapies that use patients' immune systems to fight cancer with genetically-engineered CAR T cells. The Topanga assay, named after Topanga Beach in Malibu, uses genes originally isolated from bioluminescent marine organisms.Biomechanics of Phenylalanine Maintenance Illustrated in New Study
Fox Chase Cancer Center, Temple Health
Fox Chase Cancer Center researchers have published a groundbreaking study that describes for the first time the mechanisms of how the amount of amino acid phenylalanine (Phe) is controlled in blood. Accumulation of Phe can cause phenylketonuria (PKU), a rare genetic condition that can result in permanent neurological damage as well as behavioral abnormalities if not properly managed.Shorter Course of Radiation Therapy Effective in Treating Prostate Cancer
UCLA Jonsson Comprehensive Cancer Center
A new UCLA-led study shows that men with low- or intermediate-risk prostate cancer can safely undergo higher doses of radiation over a significantly shorter period of time and still have the same, successful outcomes as from a much longer course of treatment.Immunotherapy Looks Better Than Chemo for Merkel Cell Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
The first study of the immunotherapy drug pembrolizumab as the initial treatment for patients with a rare but aggressive form of skin cancer known as Merkel cell carcinoma reports better responses and longer survival than expected with conventional chemotherapy. The study is the longest observation to date of Merkel cell carcinoma patients treated with any anti-PD-1 immunotherapy drug used in the first line.Is It Possible to Prevent Breast Cancer Metastasis?
Fred Hutchinson Cancer Center
Researchers at Fred Hutchinson Cancer Research Center in Seattle, led by translational researcher Cyrus Ghajar, PhD, may have found a way to essentially smother cancer cells in their sleep, preventing them from ever waking up and forming deadly metastatic tumors.Overcoming Drug Resistance in HER2-Positive Breast Cancer
Roswell Park Comprehensive Cancer Center
In a new study, Roswell Park researchers led by Yuesheng Zhang, MD, PhD, report that a new HER2 inhibitor, PEPD-G278D, has the potential to overcome that drug resistance. It is a novel anticancer agent that operates on several different fronts.Antibody Could Increase Cure Rate for Blood, Immune Disorders
Stanford Cancer Institute
An antibody-based treatment can gently and effectively eliminate diseased blood-forming stem cells in the bone marrow to prepare for the transplantation of healthy stem cells, according to a study in mice by researchers at the Stanford University School of Medicine. Judith Shizuru, MD, PhD, is senior author of the study.New Therapeutic Target for Rare Pediatric Cancer
The University of Texas MD Anderson Cancer Center
MD Anderson researchers have found that malignant rhabdoid tumors, a rare pediatric cancer, may be sensitive to drugs that block the cancer cell's ability to dispose of misfolded proteins. The findings provide a therapeutic target for cancers caused by mutations in the SMARCB1 gene. Giannicola Genovese, MD, is the study's corresponding author.Noninvasive Liquid Biopsies Rapidly, Accurately Determine Response to Cancer Treatment
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Results of two clinical studies have added to evidence that blood-based liquid biopsies can accurately track lung cancer treatment responses by measuring circulating tumor DNA (ctDNA) during immunotherapy and related treatments. The new studies, described in the December issues of the journal Cancer Research, showed that tracking responses to treatment by measuring ctDNA was a more accurate way of assessing tumor growth or shrinkage than traditional imaging techniques.
Sitting, Watching TV Linked to Colorectal Cancer Risk Before Age 50
Siteman Cancer Center
A new study has identified a connection between prolonged time spent sitting while watching TV and increased risk of colorectal cancer for Americans under age 50. Young-onset colorectal cancer is increasing in the U.S. and globally, sharply contrasting with the dramatic decreases among older people, largely as a result of cancer screening initiatives. Yin Cao, ScD, MPH, is co-senior author of the study.Study Finds HIV+ Cancer Patients Benefit From Immunotherapy
Georgetown Lombardi Comprehensive Cancer Center
The immunotherapy that has revolutionized treatment of many cancers appears to offer similar benefit to cancer patients living with HIV, say researchers at Georgetown Lombardi Comprehensive Cancer Center. Their study focused on whether a relatively new class of drugs called checkpoint inhibitors is both safe and effective in patients with advanced cancer who also live with HIV.
FDA Approves New Drug for Advanced Bladder Cancer
Yale Cancer Center, Yale School of Medicine
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to the drug enfortumab vedotin (EV) to treat adult patients with advanced urothelial or bladder cancer. The approval is the direct result of a multi-institutional clinical trial led by Yale Cancer Center and Smilow Cancer Hospital researchers demonstrating EV as an effective treatment for this deadly disease.Findings Strengthen Link Between Vitamin E Acetate and Vaping-Associated Lung Injuries
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
New research by the Centers for Disease Control and Prevention, in collaboration with OSUCCC – James, strengthens prior findings on the link between vitamin E acetate and EVALI (e-cigarette or vaping product use-associated lung injury). Peter Shields, MD, led the study.Research Team Helps Explain How Chronic Stress Weakens Immunity Against Cancer
Roswell Park Comprehensive Cancer Center
In 2013, a research team from Roswell Park, led by Elizabeth Repasky, PhD, reported that chronic stress can encourage the development and proliferation of tumor cells by suppressing natural immunity against cancer. In a new study, the same laboratory has revealed that chronic stress weakens immunity against cancer through its effect on a specific cell type known as the myeloid-derived suppressor cell.Nanoparticles Deliver 'Suicide Gene' Therapy to Pediatric Brain Tumors Growing in Mice
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Johns Hopkins researchers report that a type of biodegradable, lab-engineered nanoparticle they fashioned can successfully deliver a "suicide gene" to pediatric brain tumor cells implanted in the brains of mice. The poly(beta-amino ester) nanoparticles, known as PBAEs, were part of a treatment that also used a drug to kill the cells and prolong the test animals’ survival.Proton Therapy as Effective as Standard Radiation With Fewer Side Effects
Siteman Cancer Center
Cancer patients who receive proton therapy experience similar cure rates and fewer serious side effects compared with those who undergo traditional X-ray radiation therapy, according to a study led by researchers at Washington University School of Medicine and Siteman Cancer Center in St. Louis and the Perelman School of Medicine at the University of Pennsylvania.Body Temperature May Provide Early Warning for Graft-Versus-Host Disease
University of Michigan Rogel Cancer Center
By continuously monitoring the body temperature of mice that had undergone bone-marrow transplants, researchers were able to detect early warning signs of graft-versus-host disease in a simple, non-invasive way. If similar temperature patterns can be detected in human patients, University of Michigan researchers are optimistic that wearable temperature monitors could offer a practical, low-cost method for quickly identifying patients who are developing the complication — and thus help to speed interventions and reduce mortality. Study senior author is Muneesh Tewari, MD, PhD.MEAL Study: Eating More Produce Will Not Cure, Stop Prostate Cancer
Roswell Park Comprehensive Cancer Center
National guidelines recommend that men with prostate cancer eat a vegetable-rich diet, suggesting it might decrease cancer progression and death. But in a Phase III randomized clinical trial, patients with prostate cancer assigned to eat seven or more servings of vegetables and fruits daily saw no extra protection from the increased consumption of micronutrients. The Men’s Eating and Living (MEAL) study is led by investigators from UC San Diego Moores Cancer Center and Roswell Park Comprehensive Cancer Center.Protein Inhibitor is Potential Treatment for Common Mutations in Non-Hodgkin Lymphomas
The University of Texas MD Anderson Cancer Center
A study at The University of Texas MD Anderson Cancer Center demonstrated a potential new approach to treating two of the most common subtypes of lymphoma through manipulation of molecular programs controlled by the cAMP-response element binding protein (CREBBP). Mutations of CREBBP are frequently found in follicular lymphoma and diffuse large B-cell lymphomas, and allow malignant cells to hide from the immune system.Aspirin Appears to Curb Colorectal Cancer Recurrence, Tumor Growth
City of Hope Comprehensive Cancer Center
The benefits of a daily aspirin may extend to colorectal cancer treatment, say City of Hope researchers who have found aspirin appears to reduce tumor growth and inhibit recurrence of the disease. The trick, they say, is to determine the right dosage of aspirin that can be used as a daily prophylactic without triggering dangerous side effects such as stomach and brain bleeds. Ajay Goel, PhD, is senior author of the study.Researchers Find 'Switch' That Lets Common, Cancer-Causing Virus Replicate
University of Florida Health Cancer Center
Many viruses are master manipulators, hijacking cellular functions to propagate, spread and avoid elimination by their host's immune system. Now, University of Florida researcher Sumita Bhaduri-McIntosh, MD, PhD, has discovered how the common, cancer-causing Epstein-Barr virus does just that by using a complex of proteins to emerge from a dormant state and begin replicating.Study Reveals How a Blood-Clotting Protein and Blood Platelets Promote Immune Evasion, Cancer Progression
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
A study led by researchers at OSUCCC – James reveals how a clotting protein and blood platelets can promote cancer progression and suppress immune responses to cancer. The findings show how thrombin causes blood platelets to release transforming growth factor-beta 1, which is known for promoting disease progression in certain cancers, and for suppressing immune-system responses to cancer.Surgery May Add Months, Years of Survival for Adults With Rare Brain Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
For adult patients with brainstem high-grade gliomas, surgically removing the entire tumor may add months or even years of survival beyond that offered by radiation and chemotherapy, according to results of a medical records study led by researchers at Johns Hopkins Kimmel Cancer Center. Debraj Mukherjee, MD, MPH, is study leader.Can a Second Dose of CAR T Cells Succeed When the First Fails?
Fred Hutchinson Cancer Center
Supercharged immune cells called CAR T cells have the potential to eradicate even the nastiest blood cancers. But CAR T-cell therapy is still new, with many unknowns. In adult patients, the cells sometimes don’t work to keep these aggressive cancers at bay. If they lose in round one, should doctors give these microscopic fighters another chance? And, if so, how can they improve their odds of success?Juul Delivers Substantially More Nicotine than Previous Generation E-Cigs, Cigarettes
UCSF Helen Diller Family Comprehensive Cancer Center
Juul delivers substantially more nicotine to the blood per puff than cigarettes or previous-generation e-cigarettes and impairs blood vessel function comparable to cigarette smoke, according to a new study by researchers at UC San Francisco. A caveat of this study is that it measured the impact of equal numbers of puffs of all products, whereas adult former cigarette smokers may stop their vaping session when they reach the level of nicotine they normally ingest, according to senior author Matthew Springer, PhD.In Childhood Cancer, Private Insurance Means Better Survival
UCSF Helen Diller Family Comprehensive Cancer Center
Children and young adults with pediatric cancer are less likely to be alive five and 10 years following diagnosis if their health insurance is covered by Medicaid or other government agencies, compared to those with private insurance, according to researchers at UCSF Benioff Children’s Hospitals. Lena Winestone, MD, is senior author of the study.John Mendelsohn, MD Anderson President Emeritus, Passes Away
The University of Texas MD Anderson Cancer Center
John Mendelsohn, MD, president emeritus of The University of Texas MD Anderson Cancer Center and an internationally acclaimed scientist whose research helped pioneer a new type of cancer therapy, died January 7 at his home in Houston. He was 82. The cause of death was glioblastoma, an aggressive form of brain cancer with which he was diagnosed 15 months ago.First Breast Cancer Patients Treated with GammaPod Radiotherapy
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Radiation oncologists at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) are now treating patients with the GammaPod™, a new FDA-cleared radiation therapy for early-stage breast cancer. The UMGCCC is the first to treat patients with this system, which was invented by University of Maryland School of Medicine scientists and physicians.Home-Based Cancer Care Service Launched
Huntsman Cancer Institute at the University of Utah
Huntsman Cancer Institute (HCI) at the University of Utah has launched a unique new service called Huntsman at Home. This service brings HCI-quality care into the homes of HCI patients, whose medical needs range from symptom management to end-of-life care. Huntsman at Home may also allow patients to be discharged sooner by enabling them to receive follow-up care in their own homes.
Jefferson to Pursue Purchase of Fox Chase
Sidney Kimmel Cancer Center at Jefferson Health
Thomas Jefferson University and Temple University have signed an agreement that creates an exclusive 90-day window within which to consider and negotiate the acquisition and conduct due diligence by Jefferson of the Fox Chase Cancer Center. The move opens the door to bring together complementary expertise in cancer treatment and research across the greater Philadelphia region and beyond.Developing and Sustaining an Effective and Resilient Oncology Careforce
National Cancer Policy Forum
Registration is open for a National Cancer Policy Forum workshop, February 11-12, in Washington, DC, that will examine the impact of evolving trends in cancer incidence and care on the oncology careforce. A primary goal of the workshop is to consider opportunities to enhance the delivery of high quality patient care by improving the development and support of the oncology careforce.ASTRO Announces Research Funding Opportunities
American Society for Radiation Oncology
Each year, the American Society for Radiation Oncology (ASTRO) funds radiation-specific pilot/seed grants for residents and postdocs and early career development awards for junior faculty. The application period for the following grant programs closes on February 15, 2019:- Resident Seed Grants ($25,000/one year)
- Physics Seed Grants ($25,000/one year)
- ASTRO-Breast Cancer Research Foundation (BCRF) Early-Career Development Awards ($200,000 over two years)
- ASTRO-Prostate Cancer Foundation (PCF) Early-Career Development Awards ($225,000 over three years)
Cancer Research Booms, Cancer Mortality Declines, NCI Director Says
Stanford Cancer Institute
In a speech at Stanford University, National Cancer Institute Director Norman Sharpless, MD, reported promising cancer mortality trends and described an encouraging landscape for research funding and drug approval. Dr. Sharpless and Steven Artandi, MD, PhD, director of the Stanford Cancer Institute, are pictured.Center for Community Engagement and Health Equity Launched
Yale Cancer Center, Yale School of Medicine
Yale Cancer Center (YCC) has launched the Center for Community Engagement and Health Equity. Building on YCC’s longstanding commitment to high-quality, expert, and patient-centered cancer care, screening, and prevention across the state of Connecticut, the new center is dedicated to ensuring cancer health equity and improving outcomes with an emphasis on traditionally underserved neighborhoods.Junior Investigators Win Awards for Pilot Projects
Fox Chase Cancer Center, Temple Health
Fox Chase Cancer Center has announced the results of its Pilot Project Competition for Junior Investigators, which was held last fall. The competition is funded through an American Cancer Society Institutional Research Grant.Cancer Center Jobs
No items found.
Meeting Announcements
Developing and Sustaining an Effective and Resilient Oncology Careforce
February 11, 2019
3rd Annual Mid-Atlantic Extracellular Vesicle Scientific Symposium
February 26, 2019
8:30 AM - 6:00 PM
3rd Annual Cancer Disparities Symposium
March 1, 2019
Epigenetics in Cancer Scientific Symposium
April 25, 2019
10:00 AM - 5:00 PM
This second “Epigenetics in Cancer” symposium will bring together leaders in basic and translational research to promote a better understanding of epigenetic pathways as drug targets in cancer therapy.
AACI/AACR Hill Day 2019
April 30, 2019
Hill Day will bring cancer center directors, researchers, oncologists, cancer survivors, and other advocates to Capitol Hill to build support for federal funding at the National Institutes of Health (NIH) and National Cancer Institute (NCI).
11th Annual AACI CRI Meeting
July 9, 2019
The CRI annual meeting creates opportunities for peer-to-peer networking and collaboration among clinical trials office staff at AACI's member cancer centers.
2019 AACI/CCAF Annual Meeting
October 20, 2019
The CME-accredited annual meeting of the Association of American Cancer Institutes (AACI) and the Cancer Center Administrators’ Forum (CCAF) provides an opportunity to network with and learn from peers at AACI cancer centers. The meeting will cover topics of both scientific and operational value, providing attendees with practical solutions.
4th Annual Cancer Disparities Symposium: Cultivating Science and Community Engagement to Address Cancer Health Disparities
March 6, 2020
The Case Comprehensive Cancer Center Office of Cancer Disparities Research will present the 4th Annual Cancer Disparities Symposium on March 6, 2020. The symposium will feature keynote presentations by renowned disparities researchers and community leaders, a poster session highlighting academic research and community programs, a networking session, and an interactive panel discussion.
Transdisciplinary Cancer Interception: Leveraging Biology to Improve Prevention and Detection
March 9, 2020
Presented by Huntsman Cancer Institute at the University of Utah and Nature Reviews Cancer, this conference aims to examine mechanisms at the cellular level, as well as system-wide influences. This meeting will bring together experts, fosteringcross-disciplinary discussions on cutting-edge research. An important goal will be to discern pathways for translating scientific discoveries in these areas into the clinic and general population.
Webinar Series - Part 2: FDA Audit Readiness for Research Sites
March 10, 2020
The ASCO Research Community Forum is hosting a free 2-part webinar series on FDA audit readiness, which will take participants on a journey through the FDA inspection process.
The first webinar, on February 13, 2020, included reflections from FDA and a principal investigator. The second webinar, on March 10, 2020, will offer strategies for effective pre-audit preparation and post-audit follow-up.
This activity is approved for AMA PRA Category 1 Credit™ and nursing continuing education credits.
The first webinar, on February 13, 2020, included reflections from FDA and a principal investigator. The second webinar, on March 10, 2020, will offer strategies for effective pre-audit preparation and post-audit follow-up.
This activity is approved for AMA PRA Category 1 Credit™ and nursing continuing education credits.
Immunotherapy of Cancer: From CAR T Cells to Checkpoint Inhibitors
March 18, 2020
DUE TO THE CORONAVIRUS OUTBREAK, THIS EVENT HAS BEEN CANCELED.
City of Hope Comprehensive Cancer Center will host a two-and-a-half day symposium that addresses the immunologic basis for cellular immunotherapies and how to select and manage patients.
A pre-conference nursing workshop will be held at 5:00 pm Pacific on March 18, 2020. The general session will be held March 19-21.
City of Hope Comprehensive Cancer Center will host a two-and-a-half day symposium that addresses the immunologic basis for cellular immunotherapies and how to select and manage patients.
A pre-conference nursing workshop will be held at 5:00 pm Pacific on March 18, 2020. The general session will be held March 19-21.